Statin therapy for the prevention of atrial fibrillation: A meta-analysis of randomized controlled trials

Pharmacotherapy

Volumn 31, Issue 11, 2011, Pages 1051-1062

  Wang, Zhongsu ^a,b   Zhang, Yong ^a   Gao, Mei ^a   Wang, Jiangrong ^a   Wang, Qing ^a   Wang, Xiaojun ^a   Su, Lequn ^a   Hou, Yinglong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitor; Atrial fibrillation; Meta analysis; Statin

Indexed keywords

3 HYDROXY 3 METHYLGLUTARIC ACID; ATORVASTATIN; CERIVASTATIN; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; EFFECT SIZE; EMBASE; HEART ATRIUM FIBRILLATION; HUMAN; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RISK; SECONDARY PREVENTION;

ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION;

EID: 80054947497     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.11.1051     Document Type: Article

References (39)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention - the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001;285:2370-5. (Pubitemid 32424106)
2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation 1998;98:946-52. (Pubitemid 28446646)
3. Kim MH, Lin J, Hussein M, Battleman D. Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy. Curr Med Res Opin 2009;25:3037-47.
4. Moro C, Hernández-Madrid A, Matía R. Non-antiarrhythmic drugs to prevent atrial fibrillation. Am J Cardiovasc Drugs 2010;10:165-73.
5. Camm AJ, Kirchhof P, Lip GY, et al., for the European Heart Rhythm Association, European Association for Cardio- Thoracic Surgery. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
6. Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003;92:1379-83. (Pubitemid 37532555)
7. Ozaydin M, Dogan A, Varol E, et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 2007;107:117-21.
8. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005;150:1064.e7-12.
9. Schwartz GG, Olsson AG, Chaitman B, et al. Effect of intensive statin treatment on the occurrence of atrial fibrillation after acute coronary syndrome: an analysis of the MIRACL trial [abstract]. Circulation 2004;110(suppl):S740.
10. Maggioni AP, Fabbri G, Lucci D, et al., for the GISSI-HF Investigators. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J 2009;30:2327-36.
11. Macfarlane PW, Norrie J, for the WOSCOPS Executive Committee. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland coronary prevention study. J Electrocardiol 2007;40:101-9. (Pubitemid 44958596)
12. Almroth H, Höglund N, Boman K, et al. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur Heart J 2009;30:827-33.
13. Xia W, Yin Z, Li J, Song Y, Qu X. Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin Electrophysiol 2009;32:1562-6.
14. Tveit A, Grundtvig M, Gundersen T, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004;93:780-2. (Pubitemid 38338579)
15. Ozaydin M, Varol E, Aslan SM, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006;97:1490-3.
16. White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000;343:317-26. (Pubitemid 30616697)
17. Ji Q, Mei Y, Wang X, et al. Effect of preoperative atorvastatin therapy on atrial fibrillation following off-pump coronary artery bypass grafting. Circ J 2009;73:2244-9.
18. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (atorvastatin for reduction of myocardial dysrhythmia after cardiac surgery) study. Circulation 2006;114:1455-61. (Pubitemid 44526999)
19. Mannacio VA, Iorio D, De Amicis V, et al. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg 2008;136:1541-8.
20. Spadaccio C, Pollari F, Casacalenda A, et al. Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study. J Cardiovasc Pharmacol 2010;55:30-8.
21. Tamayo E, Alvarez FJ, Alonso O, et al. Effects of simvastatin on systemic inflammatory responses after cardiopulmonary bypass. J Cardiovasc Surg (Torino) 2009;50:687-94.
22. Chello M, Patti G, Candura D, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 2006;34:660-7.
23. Caorsi C, Pineda F, Munoz C. Pravastatin immunomodulates IL-6 and C-reactive protein, but not IL-1 and TNF-alpha, in cardio-pulmonary bypass. Eur Cytokine Netw 2008;19:99-103.
24. Song YB, On YK, Kim JH, et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J 2008;156:373.e9-16.
25. Tsai CT, Lai LP, Hwang JJ, et al. Atorvastatin prevents atrial fibrillation in patients with bradyarrhythmias and implantation of an atrial-based or dual-chamber pacemaker: a prospective randomized trial. Am Heart J 2008;156:65-70.
26. Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (antihypertensive and lipid-lowering treatment to prevent heart attack trial). J Am Coll Cardiol 2009;54:2023-31.
27. Fauchier L, Pierre B, de Labriolle A, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008;51:828-35. (Pubitemid 351255618)
28. Chen WT, Krishnan GM, Sood N, Kluger J, Coleman CI. Effect of statins on atrial fibrillation after cardiac surgery: a duration- and dose-response meta-analysis. J Thorac Cardiovasc Surg 2010;140:364-72.
29. Higgins JPT, Green S. Assessing risk of bias in included studies. In: Cochrane handbook for systematic reviews of interventions, version 5.0.2, updated September 2009. Available from www.cochrane-handbook.org. Accessed March 1, 2010.
30. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. Chichester, UK, Wiley, 2009.
31. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. (Pubitemid 27387172)
32. Hadi HA, Mahmeed WA, Suwaidi JA, Ellahham S. Pleiotropic effects of statins in atrial fibrillation patients: the evidence. Vasc Health Risk Manag 2009;5:533-51.
33. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10. (Pubitemid 37553570)
34. Ridker PM, Cannon CP, Morrow D, et al., for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8. (Pubitemid 40075677)
35. Schmermund A, Achenbach S, Budde T, et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation 2006;113:427-37. (Pubitemid 43803205)
36. McLean DS, Ravid S, Blazing M, Gersh B, Shui A, Cannon CP. Effect of statin dose on incidence of atrial fibrillation: data from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. Am Heart J 2008;155:298-302.
37. Kourliouros A, Valencia O, Hosseini MT, et al. Preoperative high-dose atorvastatin for prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. J Thorac Cardiovasc Surg 2011;141:244-8.
38. Sterne JA, Egger M, Smith GD. Investigating and dealing with publication and other biases. In: Egger M, Smith GD, Altman DG, eds. Systematic reviews in health care: meta-analysis in context, 2nd ed. London, United Kingdom: BMJ Books, 2001.
39. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001;323:101-5. (Pubitemid 32681979)